YS Biopharma Co., Ltd.
YS · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$99,982 | -$433,465 | -$145,479 | -$546 |
| Dep. & Amort. | $36,652 | $42,185 | $36,688 | $31,154 |
| Deferred Tax | -$4,312 | -$21,729 | $1,134 | $4,937 |
| Stock-Based Comp. | $13,557 | $9,790 | $3,505 | $7,764 |
| Change in WC | -$115,381 | -$45,789 | -$92,746 | -$64 |
| Other Non-Cash | $48,485 | $153,778 | $4,424 | -$3 |
| Operating Cash Flow | -$120,982 | -$295,230 | -$182,469 | -$613 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$12,709 | -$44,251 | -$57,050 | -$298,932 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | -$200,000 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | -$4,298 | $0 | $0 | $0 |
| Investing Cash Flow | -$17,007 | -$44,251 | -$56,982 | -$200,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$3,581 | -$78,935 | $100,877 | $364,558 |
| Stock Issued | $0 | $284,196 | $0 | $201,859 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $284,196 | $216,573 | -$163,060 |
| Financing Cash Flow | -$3,581 | $205,261 | $317,450 | $201,498 |
| Forex Effect | $2,503 | $10,400 | $21,304 | -$11,478 |
| Net Chg. in Cash | -$139,066 | -$123,819 | $99,302 | -$389,572 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $246,551 | $370,370 | $271,068 | $390,457 |
| End Cash | $107,485 | $246,551 | $370,370 | $885 |
| Free Cash Flow | -$138,840 | -$339,480 | -$239,519 | -$299,545 |